The committee noted that semaglutide tablets 3 mg, 7 mg, and 14 mg are approved for marketing in India. The firm has claimed ...

Viking's Q1 earnings show no revenue, increased R&D spending, and a substantial cash reserve, positioning it well for future ...

The global Oral Proteins & Peptides Market , valued at US$7.35 billion in 2024, is forecasted to grow at a robust CAGR of ...

Tablets of semaglutide (currently sold in injectable form as Wegovy for obesity and Ozempic for diabetes), made by the Danish firm Novo Nordisk, could reach the UK as early as next year. Drug firms ...

Savvy pharma-stock investors know that an oral GLP-1 drug from Novo Nordisk called Rybelsus has been on the market as a ...

Novo Nordisk markets its semaglutide drugs as Ozempic pre-filled pen and Rybelsus oral tablet for type II diabetes and as Wegovy injection for weight management. Lilly’s Cardiometabolic Health ...

Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their GLP-1 products. Lilly markets its dual GIP and GLP-1 receptor agonist, ...

Novo Nordisk has struck back in its growing rivalry ... The OASIS 1 study showed that a once-daily, 50 mg dose of semaglutide achieved weight loss of 15% to 17% over a 68-week period.

The daily tablet produced blood-sugar reductions on ... The needles used to inject Novo Nordisk's and Eli Lilly's GLP-1 drugs are relatively slim, but there are still plenty of folks who won ...